Sodium bis[2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-)

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1978-03-15 to 1978-03-29

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1979

Report date:

1979

Materials and methods

Principles of method if other than guideline:

according to BASF-internal standard

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Sodium bis[2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-)

EC Number:

255-527-0

EC Name:

Sodium bis[2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-)

Cas Number:

41741-86-0

Molecular formula:

C34 H24 Cr N8 O6 .Na

IUPAC Name:

Sodium;chromium(3+);2-[(3-methyl-5-oxido-1-phenylpyrazol-4-yl)diazenyl]benzoate

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Diet: ad libitum, HERILAN MRH-Haltung (single diet for housing of mice, rats and hamsters) from Heinrich EGGERSMANN KG, Rinteln
- Weight at study initiation (all concentrations): 30 g (males), 24 g (females)

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

CMC (carboxymethyl cellulose)

Details on exposure:

Suspension in 0.5 % aqueous CMC.
Test concentrations used: 2, 7 and 20 %

Doses:

200, 700, 2000 mg/kg

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
* Observations done from <1hour until 14 days after application
* Weighting at start of trial and on days 2, 7 and 13 (2000 mg/kg dose); at start of trial and on days 1, 7 and 13 (700 and 200 mg/kg dose)
- Necropsy of survivors performed: yes (on day 14)
- Other examinations performed: clinical signs

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Mortality:

At 2000 mg/kg two of five male mice died within 15 minutes after application

Clinical signs:

Short-termed deteriorated general state; time of deaths within 15 minutes; unspecific symptoms (dyspnoea, apathy, stagger, tremor)

Body weight:

Initial body weight stagnation

Gross pathology:

Animals that died (2 males): intra-abdominal substance residues
Sacrificed animals: intra-abdominal substance residues (200 and 700 mg/kg) and intra-abdominal substance incorporations (2000 mg/kg)

Any other information on results incl. tables

Weight development during test:

 

Mean body weight of mice during trial (2000 mg/kg):

- Day 2: 90 g (3 males), 120 g (5 females)

- Day 13: 112 g (3 males), 142 g (5 females)

 

Mean body weight of mice during trial (700 mg/kg):

- Day 1: 155 g (5 males), 118 g (5 females)

- Day 13: 188 g (5 males), 140 g (5 females)

 

Mean body weight of mice during trial (200 mg/kg):

- Day 2: 166 g (5 males), 127 g (5 females)

- Day 13: 193 g (5 males), 136 g (5 females)

 

 

Further detection of clinical symptoms:
 
2000 mg/kg application:
-      clear symptoms of irregular respiration up to 5 hours after application and sporadically clear symptoms 1 day after application
-      clear to strong symptoms of tremor up to 30 minutes after application
-      clear symptoms of convulsion up to 15 minutes after application
-      poorly developed signs of bad general condition up to 30 minutes after application, but good condition afterwards until end of the test
 
700 mg/kg application:
-      poor signs of irregular respiration, apathy and tremor at 30 min and 2 hours after application, after 4 hours sporadically poor signs
-      sporadically poor symptoms on skin and fur after 4 hours
-      good general condition during test, except of 30 min, 2 and 4 hours after application (partly poor signs of bad general condition)
 
200 mg/kg application:
-      poor signs of irregular respiration, apathy, tremor and poor symptoms on skin and fur at 1 day after application
- good general condition during test, except of day 1 (partly poor signs of bad general condition)

Applicant's summary and conclusion

Conclusions:

LD50 (male/female) of >2000 mg/kg